<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00593112</url>
  </required_header>
  <id_info>
    <org_study_id>2005-P-002180</org_study_id>
    <nct_id>NCT00593112</nct_id>
  </id_info>
  <brief_title>Proton Magnetic Spectroscopy in Children and Adolescents With ADHD Before and After Treatment With OROS Methylphenidate</brief_title>
  <official_title>A Pilot Study of Proton Magnetic Spectroscopy in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD) Before and After Treatment With Osmotic-controlled Release Oral Delivery System (OROS) Methylphenidate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be an open label study using daily does of up to 126mg/day of Concerta in the
      treatment of children and adolescents, ages 12-17, who meet DSM-IV criteria for ADHD.
      Specific hypotheses are as follows:

      Hypothesis 1: Children and adolescents with ADHD will have significantly higher ACC and DLPFC
      Glutamate/myo-Inositol containing compounds (Glu/Ino) and Glutamate/creatine +
      phosphocreatine (Glu/Cr) than matched HCS.

      Hypothesis 2: After six weeks of treatment, OROS methylphenidate will lower ACC and DLPFC
      Glu/Ino and Glu/Cr levels in children with ADHD who are methylphenidate responders.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to use 1H MRS to assess Glutamate (Glu), myo-Inositol
      (Ino), and creatine + phosphocreatine (Cr) levels in brain regions of interest in 20 children
      with ADHD between the ages of 12-17 years old, before and after a six-week open treatment
      trial with OROS methylphenidate. For comparison, 1H MRS will also be obtained from 20
      controls matched by age and gender. We also will scan 20 children with ADHD between the ages
      of 12-17 years old that are currently enrolled in the protocol entitled &quot;Prevention of
      Cigarette Smoking in ADHD Youth with Concerta&quot; (2003-P-001313) and on a stable dose of
      Concerta. These 20 children will be scanned once while on medication and once while off
      medication
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proton Magnetic Resonance Spectroscopy (H MRS) Scan Results - Glutamate(Glu)/Myo-inositol-containing Compounds (Ino)</measure>
    <time_frame>after 6 weeks Concerta treatment</time_frame>
    <description>Comparison of treated ADHD participants (6 weeks on Concerta) and Healthy Control Subjects (HCS)
This measure is a ratio of Glutamate (excitatory neurotransmitter) to myo-inositol (cyclic sugar alcohol) containing compounds in the anterior cingulate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>H MRS Scan Results - Glutamine (Gln)/Ino</measure>
    <time_frame>after 6 weeks Concerta treatment</time_frame>
    <description>Comparison of treated ADHD participants (6 weeks on Concerta) and Healthy Control Subjects (HCS)
This measure is a ratio of Glutamine (amino acid precursor to Glu) to myo-inositol (cyclic sugar alcohol) containing compounds in the anterior cingulate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>H MRS Scan Results - Glutamate &amp; Glutamine (Glx)/Ino</measure>
    <time_frame>after 6 weeks Concerta treatment</time_frame>
    <description>Comparison of treated ADHD participants (6 weeks on Concerta) and Healthy Control Subjects (HCS)
This measure is a ratio of Glutamate and it's precursor, Glutamine, to myo-inositol (cyclic sugar alcohol) containing compounds in the anterior cingulate.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>ADHD</condition>
  <arm_group>
    <arm_group_label>OROS Methylphenidate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Healthy Volunteer Control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OROS methylphenidate</intervention_name>
    <description>Concerta is given in capsule form with a minimum dose of 18 mg/day and a max of 126 mg/day. Subjects take Concerta once per day for 6 weeks.</description>
    <arm_group_label>OROS Methylphenidate</arm_group_label>
    <other_name>Concerta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>No intervention</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female subjects, 12-17 years of age.

          2. ADHD subjects must meet study criteria for the &quot;Prevention of Cigarette Smoking in
             ADHD Youth with CONCERTA Protocol&quot;; #2003-P-001313.

          3. Control subjects must not meet full DSM-IV criteria for Attention Deficit
             Hyperactivity Disorder, or any other current major psychiatric disorder.

          4. Each subject and his/her authorized legal representative must understand the nature of
             this proposed study, and must sign informed consent and informed assent documents.

          5. Subject and parent must have a level of understanding sufficient to communicate
             intelligently with the investigator and study coordinator, and to cooperate with study
             procedures.

        Exclusion Criteria:

          1. Clinically significant chronic medical condition including hepatic, renal,
             gastroenterologic, respiratory, cardiovascular (including ischemic heart disease),
             endocrinologic, neurologic, immunologic, or hematologic disease.

          2. Organic brain disorders or mental retardation (I.Q. &lt;75).

          3. Contraindication to MRI including presence of metal or surgical devices (plates,
             implants, braces or other items).

          4. Pregnancy; women of child bearing potential must be using a medically approved method
             of birth control. Women of child bearing potential will receive a urinary pregnancy
             test prior to each MR scanning session.

          5. Severe phobia of being in small, enclosed spaces.

          6. Investigator and his/her immediate family; defined as the investigator's spouse,
             parent, child, grandparent, or grandchild will not be eligible to participate in the
             treatment arm of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Hammerness, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>Massachusetts</state>
        <zip>02138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://massgeneral.org/pediatricpsych/home.html</url>
  </link>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 28, 2007</study_first_submitted>
  <study_first_submitted_qc>January 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2008</study_first_posted>
  <results_first_submitted>January 7, 2011</results_first_submitted>
  <results_first_submitted_qc>April 6, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 5, 2011</results_first_posted>
  <last_update_submitted>August 22, 2012</last_update_submitted>
  <last_update_submitted_qc>August 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 31, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Paul Hammerness, MD</investigator_full_name>
    <investigator_title>Clinical Investigator, Clinical and Research Program in Pediatric Psychopharmacology and Adult ADHD</investigator_title>
  </responsible_party>
  <keyword>HMRS Scanning</keyword>
  <keyword>ADHD</keyword>
  <keyword>Child</keyword>
  <keyword>Adolescent</keyword>
  <keyword>HMRS Scans</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylphenidate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>OROS Methylphenidate</title>
          <description>OROS = Osmotic-controlled Release Oral delivery System</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>Healthy Volunteer Control group</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Scan Anxiety</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal Scan</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unreadable Scan</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>OROS Methylphenidate</title>
          <description>OROS = Osmotic-controlled Release Oral delivery System</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>Healthy Volunteer Control group</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="39"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proton Magnetic Resonance Spectroscopy (H MRS) Scan Results - Glutamate(Glu)/Myo-inositol-containing Compounds (Ino)</title>
        <description>Comparison of treated ADHD participants (6 weeks on Concerta) and Healthy Control Subjects (HCS)
This measure is a ratio of Glutamate (excitatory neurotransmitter) to myo-inositol (cyclic sugar alcohol) containing compounds in the anterior cingulate.</description>
        <time_frame>after 6 weeks Concerta treatment</time_frame>
        <population>Seven subjects who completed the protocol were not included due to a lack of baseline comparison.</population>
        <group_list>
          <group group_id="O1">
            <title>OROS Methylphenidate</title>
            <description>OROS = Osmotic-controlled Release Oral delivery System</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Healthy Volunteer Control group</description>
          </group>
        </group_list>
        <measure>
          <title>Proton Magnetic Resonance Spectroscopy (H MRS) Scan Results - Glutamate(Glu)/Myo-inositol-containing Compounds (Ino)</title>
          <description>Comparison of treated ADHD participants (6 weeks on Concerta) and Healthy Control Subjects (HCS)
This measure is a ratio of Glutamate (excitatory neurotransmitter) to myo-inositol (cyclic sugar alcohol) containing compounds in the anterior cingulate.</description>
          <population>Seven subjects who completed the protocol were not included due to a lack of baseline comparison.</population>
          <units>MRS Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" spread="0.45"/>
                    <measurement group_id="O2" value="1.56" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>H MRS Scan Results - Glutamine (Gln)/Ino</title>
        <description>Comparison of treated ADHD participants (6 weeks on Concerta) and Healthy Control Subjects (HCS)
This measure is a ratio of Glutamine (amino acid precursor to Glu) to myo-inositol (cyclic sugar alcohol) containing compounds in the anterior cingulate.</description>
        <time_frame>after 6 weeks Concerta treatment</time_frame>
        <population>Seven subjects who completed the protocol were not included due to a lack of baseline comparison.</population>
        <group_list>
          <group group_id="O1">
            <title>OROS Methylphenidate</title>
            <description>OROS = Osmotic-controlled Release Oral delivery System</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Healthy Volunteer Control group</description>
          </group>
        </group_list>
        <measure>
          <title>H MRS Scan Results - Glutamine (Gln)/Ino</title>
          <description>Comparison of treated ADHD participants (6 weeks on Concerta) and Healthy Control Subjects (HCS)
This measure is a ratio of Glutamine (amino acid precursor to Glu) to myo-inositol (cyclic sugar alcohol) containing compounds in the anterior cingulate.</description>
          <population>Seven subjects who completed the protocol were not included due to a lack of baseline comparison.</population>
          <units>MRS Ratios</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.08" spread="0.43"/>
                    <measurement group_id="O2" value="1.02" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>H MRS Scan Results - Glutamate &amp; Glutamine (Glx)/Ino</title>
        <description>Comparison of treated ADHD participants (6 weeks on Concerta) and Healthy Control Subjects (HCS)
This measure is a ratio of Glutamate and it's precursor, Glutamine, to myo-inositol (cyclic sugar alcohol) containing compounds in the anterior cingulate.</description>
        <time_frame>after 6 weeks Concerta treatment</time_frame>
        <population>Seven subjects who completed the protocol were not included due to a lack of baseline comparison.</population>
        <group_list>
          <group group_id="O1">
            <title>OROS Methylphenidate</title>
            <description>OROS = Osmotic-controlled Release Oral delivery System</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Healthy Volunteer Control group</description>
          </group>
        </group_list>
        <measure>
          <title>H MRS Scan Results - Glutamate &amp; Glutamine (Glx)/Ino</title>
          <description>Comparison of treated ADHD participants (6 weeks on Concerta) and Healthy Control Subjects (HCS)
This measure is a ratio of Glutamate and it's precursor, Glutamine, to myo-inositol (cyclic sugar alcohol) containing compounds in the anterior cingulate.</description>
          <population>Seven subjects who completed the protocol were not included due to a lack of baseline comparison.</population>
          <units>MRS Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.58" spread="0.73"/>
                    <measurement group_id="O2" value="2.59" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>OROS Methylphenidate</title>
          <description>OROS = Osmotic-controlled Release Oral delivery System</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>Healthy Volunteer Control group</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Paul Hammerness, M.D.</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-503-1040</phone>
      <email>phammerness@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

